Inside Peptides
Search
Menu

Semaglutide vs Tirzepatide: Comparing Trial Evidence

Two medicines, several different research questions. Direct trials compare blood glucose or body weight in specific populations. Separate cardiovascular and kidney trials cannot determine which medicine is better for every patient.

FDA Approved FDA Approved Active Comparator RCT Available
Scientific comparison banner depicting semaglutide single GLP-1 receptor binding alongside tirzepatide dual GIP and GLP-1 receptor binding.
Comparative incretin pharmacology: Selective GLP-1 receptor targeting (Semaglutide) contrasted with dual GIP and GLP-1 receptor co-agonism (Tirzepatide). Illustration © Inside Peptides.
Evidence-Based Short Answer

Evidence-Based Summary

Direct randomized studies favor tirzepatide for average HbA1c reduction versus injectable semaglutide 1 mg in adults with type 2 diabetes (SURPASS-2, 2021), and for average weight reduction versus maximum-tolerated injectable semaglutide in adults with obesity without diabetes (SURMOUNT-5, 2025). These findings answer different questions and do not establish superiority for cardiovascular events, kidney outcomes, every formulation or every patient. SURPASS-CVOT was published in 2025: it compared tirzepatide with dulaglutide, not semaglutide.

Medical disclaimer: Inside Peptides provides educational, evidence-first scientific analysis. Choosing between prescribed incretin therapies depends on specific clinical indications, cardiovascular risk profiles, patient comorbidities, formulation preferences, and individual medical supervision. We do not provide treatment recommendations.
At a Glance

Quick Comparison: Semaglutide vs Tirzepatide

A high-level comparison of molecule class, molecular receptor targets, FDA regulatory approvals, and verified clinical programs.

Table 1: Verified regulatory, pharmacological, and clinical comparison between Semaglutide and Tirzepatide.
Feature Semaglutide Tirzepatide
Receptor targets GLP-1 receptor: a cell-surface receiver for an incretin signal GIP and GLP-1 receptors: two incretin signal receivers
Direct glucose comparison SURPASS-2: injectable semaglutide 1 mg; type 2 diabetes on metformin SURPASS-2: three tirzepatide regimens; 40 weeks
Direct weight comparison SURMOUNT-5: maximum-tolerated injectable semaglutide; no diabetes SURMOUNT-5: maximum-tolerated tirzepatide; 72 weeks
Cardiovascular comparator SELECT: placebo, established cardiovascular disease without diabetes SURPASS-CVOT: dulaglutide, type 2 diabetes with atherosclerotic disease
Approved formulations and indications Product-specific injectable and oral semaglutide labels; see current prescribing information below Mounjaro and Zepbound injectable labels; diabetes, weight and sleep-apnea indications differ by product
Receptor Biology & Transduction

How Semaglutide and Tirzepatide Function at the Receptor Level

Incretins are hormones that help coordinate insulin release after food. An agonist activates a receptor. Adding a second target does not by itself prove a clinical advantage.

Molecular mechanism diagram comparing semaglutide single GLP-1 receptor engagement with tirzepatide dual GIP and GLP-1 receptor engagement.
Figure 1: Mechanism of action. Semaglutide selectively stimulates the GLP-1 receptor, promoting cAMP-dependent insulin secretion, glucagon suppression, and central satiety. Tirzepatide engages both GIP and GLP-1 receptors, exhibiting biased GLP-1 signaling (favoring cAMP over β-arrestin recruitment) and adipose lipid buffering via GIP signaling. Diagram © Inside Peptides.
Semaglutide Target

Semaglutide

Primary Target: GLP-1 receptor

Affinity Profile: Selective GLP-1 receptor agonist

Activates GLP-1 signaling, helping glucose-dependent insulin release and reducing food intake. Pharmacology is distinct from evidence for a particular health outcome.

Tirzepatide Target

Tirzepatide

Primary Targets: GIP and GLP-1 receptors

Affinity Profile: Dual receptor agonist

Activates both incretin receptors. Human trials test the medicine as a whole; they do not isolate how much of a weight or glucose effect comes from each receptor.

Regulatory Status

FDA Approvals, Formulations, and Clinical Indications

United States prescribing information checked 10 October 2026. Approved use belongs to the named product, formulation and population, rather than every product containing the same molecule.

FDA Approved

Semaglutide Status & Formulations

United States, verified 10 October 2026: Ozempic injection covers type 2 diabetes and specified cardiovascular/kidney risk indications. Oral Rybelsus/Ozempic tablets have their own diabetes and cardiovascular indications. Wegovy injection and tablets cover defined weight and cardiovascular indications; pediatric and MASH indications differ by formulation. Injectable Wegovy’s adult noncirrhotic MASH indication (F2–F3 fibrosis) is accelerated approval with confirmatory requirements. Sharing an ingredient does not make labels interchangeable.

FDA Approved

Tirzepatide Status & Formulations

United States, verified 10 October 2026: Mounjaro is indicated for glycemic control in adults and children aged 10 years and older with type 2 diabetes. Zepbound covers defined adult weight-management indications and moderate-to-severe obstructive sleep apnea in adults with obesity. Each label has its own eligibility and limitations; neither brand is a universal treatment for metabolic symptoms.

Critical Regulatory Distinction

Consult the current product labels linked in References. Approval is separate from a research result. Compounded products are not FDA-approved equivalents of approved medicines.

Clinical Evidence Programs

Trial Architecture: SUSTAIN/STEP vs SURPASS/SURMOUNT

HbA1c measures average blood glucose; weight change measures body mass. A cardiovascular composite combines specified events. These endpoints cannot be substituted for one another.

Semaglutide: Clinical Evidence Overview

SELECT randomized 17,604 adults with established cardiovascular disease and overweight or obesity without diabetes. Events occurred in 6.5% versus 8.0% with placebo over mean 39.8-month follow-up (hazard ratio 0.80, 95% CI 0.72–0.90). FLOW randomized 3,533 adults with type 2 diabetes and chronic kidney disease; its kidney/CV-death composite favored semaglutide (HR 0.76, 95% CI 0.66–0.88). Neither compared tirzepatide.

Tirzepatide: Clinical Evidence Overview

SURPASS-CVOT randomized 13,299 participants with type 2 diabetes and atherosclerotic cardiovascular disease; its modified intention-to-treat analysis included 13,165. Events occurred in 12.2% with tirzepatide versus 13.1% with dulaglutide (HR 0.92, 95.3% CI 0.83–1.01). It met noninferiority but not superiority (P=0.09 for superiority). This is not a direct comparison with semaglutide.

Active-Comparator RCT

Direct Head-to-Head Evidence: The SURPASS-2 Trial

SURPASS-2 and SURMOUNT-5 provide direct randomized evidence, whereas comparing separate STEP and SURMOUNT placebo trials is an indirect comparison. Diabetes status, baseline characteristics, duration, background care and statistical estimand can change results.

SURPASS-2: Phase 3 Active-Comparator Trial (NEJM 2021)

Head-to-Head RCT

ClinicalTrials.gov: NCT03987919 · Study Design: Open-label, 40-week, parallel-group, multicenter randomized controlled trial.

Participant Population: 1,879 adults with type 2 diabetes on metformin; 40-week follow-up.

Assigned Interventions: Three tirzepatide groups versus injectable semaglutide 1 mg; these trial regimens are context, not prescribing instructions.

Primary Endpoint: Change in glycated hemoglobin (HbA1c) from baseline at week 40.

Direct Head-to-Head Findings

Table 2: Primary and key secondary outcomes from the SURPASS-2: Phase 3 Active-Comparator Trial (NEJM 2021) trial.
Outcome Measure Semaglutide Tirzepatide Statistical Significance & Findings
HbA1c change (percentage points, not percent relative change) -1.86% (Semaglutide 1.0 mg) -2.01% (Tirzepatide 5 mg); -2.24% (10 mg); -2.30% (15 mg) All tirzepatide doses met criteria for non-inferiority and statistical superiority over semaglutide 1.0 mg (estimated treatment differences: -0.15% [5 mg], -0.39% [10 mg], -0.45% [15 mg]; p<0.001 for 10 mg and 15 mg).
Mean body weight reduction -5.7 kg -7.6 kg, -9.3 kg and -11.2 kg across tirzepatide groups Tirzepatide produced statistically significantly greater mean weight loss across all evaluated doses (differences vs semaglutide: -1.9 kg [5 mg], -3.6 kg [10 mg], -5.5 kg [15 mg]; all p<0.001).

Safety in SURPASS-2: Phase 3 Active-Comparator Trial (NEJM 2021)

Gastrointestinal adverse events were common in both groups. An open-label trial and a specific comparator regimen cannot establish which medicine is safest for every person.

Essential Methodological Limitations

  • Open-label: participants and investigators knew treatment assignment.
  • Semaglutide 1 mg injection was the comparator, not all current doses or oral formulations.
  • Adults with type 2 diabetes on metformin are not interchangeable with adults without diabetes.
  • SURMOUNT-5 was published in 2025: among 751 adults without diabetes, mean weight change at 72 weeks was −20.2% with tirzepatide versus −13.7% with semaglutide. The open-label, maximum-tolerated-regimen result is not evidence of cardiovascular superiority.
Evidence Matrix

Curated Clinical Evidence Table

A curated selection of the primary studies behind each compound’s evidence profile. Results from different studies are not directly comparable.

Table 3: Key studies evaluating Semaglutide and Tirzepatide.
Study & Citation Population Comparison & Dosing Duration Main Endpoint Key Finding Methodological Limitations
SURPASS-2 (Frías et al., NEJM 2021) 1,879 adults with Type 2 diabetes on metformin Tirzepatide (5, 10, 15 mg) vs Semaglutide 1.0 mg weekly 40 weeks Change in HbA1c and body weight Tirzepatide 15 mg achieved greater HbA1c reduction (-2.30% vs -1.86%) and weight loss (-11.2 kg vs -5.7 kg) than semaglutide 1.0 mg (all p<0.001). Open-label; semaglutide dose limited to 1.0 mg; T2D population only.
STEP 1 (Wilding et al., NEJM 2021) 1,961 adults with obesity/overweight without diabetes Semaglutide 2.4 mg weekly vs Placebo (both + lifestyle) 68 weeks Percentage change in body weight Mean body weight reduction of -14.9% with semaglutide 2.4 mg vs -2.4% with placebo. Placebo-controlled; not an active comparator trial.
SURMOUNT-1 (Jastreboff et al., NEJM 2022) 2,539 adults with obesity/overweight without diabetes Tirzepatide (5, 10, 15 mg) weekly vs Placebo (+ lifestyle) 72 weeks Percentage change in body weight Mean weight reductions of -15.0% (5 mg), -19.5% (10 mg), and -20.9% (15 mg) vs -3.1% with placebo. Placebo-controlled; differences across STEP 1 and SURMOUNT-1 cannot be directly cross-compared without head-to-head controls.
SELECT (Lincoff et al., NEJM 2023) 17,604 adults ≥45y with CVD & overweight/obesity without diabetes Semaglutide 2.4 mg weekly vs Placebo (+ standard of care) Mean 39.8 months Time to first 3-point MACE (CV death, nonfatal MI, nonfatal stroke) 20% relative risk reduction in MACE (HR 0.80, 95% CI 0.72–0.90; p<0.001); led to landmark FDA approval. Placebo comparison; does not establish superiority over tirzepatide or a class-wide effect.
SURMOUNT-5 (Aronne et al., 2025) 751 adults with obesity without diabetes Maximum-tolerated tirzepatide versus injectable semaglutide 72 weeks Percentage weight change −20.2% versus −13.7% (P<0.001). Open-label; weight endpoint, not a cardiovascular-outcomes comparison.
SURPASS-CVOT (Nicholls et al., 2025) 13,299 randomized; 13,165 analyzed, type 2 diabetes and atherosclerotic cardiovascular disease Tirzepatide versus dulaglutide Event-driven follow-up Cardiovascular death, myocardial infarction or stroke 12.2% versus 13.1%; HR 0.92 (95.3% CI 0.83–1.01). Noninferior, not superior. Not a semaglutide comparison; active comparator, not placebo.
Safety & Tolerability Profile

Adverse Effects, Boxed Warnings, and Clinical Precautions

Because both semaglutide and tirzepatide stimulate incretin receptors and slow upper gastrointestinal transit, they share broad safety considerations alongside specific drug-interaction nuances.

Boxed Warning

FDA Boxed Warning: Risk of Thyroid C-Cell Tumors

Both U.S. labels carry a Boxed Warning for Thyroid C-Cell Tumors observed in rodents; whether these medicines cause such tumors in humans is unknown. Both are contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2. This is a labeling warning, not a measured human cancer incidence.

Table 4: Evidence-supported safety considerations and adverse-reaction frequency for Semaglutide and Tirzepatide.
Safety Consideration Semaglutide Tirzepatide
Common adverse effects Gastrointestinal symptoms including nausea, vomiting and diarrhea; frequencies depend on product and trial Gastrointestinal symptoms including nausea, vomiting and diarrhea; frequencies depend on product and trial
Important label warnings Pancreatitis, gallbladder disease and dehydration-associated kidney injury; see product-specific label Pancreatitis, gallbladder disease and dehydration-associated kidney injury; see product-specific label
Hypoglycemia Risk can increase with insulin or insulin secretagogues Risk can increase with insulin or insulin secretagogues
Oral contraceptive interaction See current formulation-specific prescribing information Label specifies a non-oral contraceptive or additional barrier method after initiation and dose increases

Specific Drug Interaction Note

Tirzepatide labels advise a non-oral contraceptive method or an additional barrier method for four weeks after initiation and each dose increase because delayed gastric emptying can affect oral contraceptive absorption. This is a drug-interaction warning; individual contraceptive decisions require clinical advice.

Pharmacological Commonalities

What Semaglutide and Tirzepatide Have in Common

Where the two compounds overlap in biology, evidence or regulatory context.

Both have randomized human evidence

Evidence supports defined populations and outcomes, with product-specific indications.

Shared safety considerations

Gastrointestinal effects and the rodent-based thyroid warning appear in both labels.

Distinguishing Features

Key Scientific & Clinical Differences

Meaningful distinctions in mechanism, strength of evidence, safety and regulatory status.

One target versus two

Semaglutide activates GLP-1 receptors; tirzepatide activates GIP and GLP-1 receptors.

Different comparisons answer different questions

SURMOUNT-5 directly compares weight outcomes; SELECT and SURPASS-CVOT have different comparators and populations.

Inside Peptides Editorial Policy

Scientific Comparison vs Clinical Recommendations

Inside Peptides compares scientific evidence, receptor pharmacology, and official regulatory documents to advance public and professional understanding. We do not determine which compound is appropriate for an individual patient, rank medications with arbitrary scores, or recommend initiating or switching treatments.

Decisions about any medicine require a licensed healthcare professional who can weigh personal medical history, contraindications, interactions and monitoring needs. Unapproved peptides have no established safe use, and products sold as “research chemicals” are not the preparations studied in clinical research.

Evidence Verification

Approved Uses vs Online Claims

A critical scientific distinction between verified, FDA-approved clinical uses and unverified claims circulating on social media and vendor platforms.

Greater average weight loss means fewer heart attacks than semaglutide

Not established by the weight trial
Regulatory Context:

Use the primary trials and product-specific labels.

Scientific Reality:

A body-weight endpoint is not a cardiovascular-events endpoint. SELECT and SURPASS-CVOT do not form a randomized semaglutide-versus-tirzepatide comparison.

Claim-Level Certainty

Evidence Strength Across Clinical Domains

Inside Peptides evaluates scientific certainty at the claim level. Because clinical evidence varies significantly depending on the therapeutic endpoint evaluated, each domain is assessed independently.

Weight in adults without diabetes

Direct SURMOUNT-5 evidence favors tirzepatide on average in its defined 72-week comparison.

Semaglutide: Strong Evidence
Tirzepatide: Strong Evidence

Blood glucose in type 2 diabetes

Direct SURPASS-2 evidence compares tirzepatide with semaglutide 1 mg, not every formulation.

Semaglutide: Strong Evidence
Tirzepatide: Strong Evidence

Cardiovascular comparison between these two medicines

The trials described here do not directly compare semaglutide and tirzepatide for cardiovascular events.

Semaglutide: Insufficient Evidence
Tirzepatide: Insufficient Evidence
Unresolved Questions

What Research Still Doesn’t Tell Us

Identifying open scientific questions, pending active-comparator trials, and areas where long-term clinical data remain incomplete.

Individual outcomes

Group averages do not predict an individual response, tolerability or the appropriate prescription.

Direct long-term organ outcomes

A direct weight comparison does not settle comparative cardiovascular or kidney outcomes.

Cross-trial estimates

Different populations, regimens, follow-up and handling of treatment discontinuation limit simple league tables. Both head-to-head trials were funded by Eli Lilly; SELECT and FLOW by Novo Nordisk.

Related Compound Profiles

Individual profiles provide full molecular datasheets, CAS numbers, preclinical histories, and compound monographs.

Bibliography & Sources

Scientific & Regulatory References

Every pharmacological mechanism, clinical trial result, and regulatory approval cited on this page is traceable to official FDA prescribing documentation, ClinicalTrials.gov registries, or peer-reviewed medical publications.

  1. Randomized controlled trial · Head-to-head
    Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
    Frías JP, Davies MJ, Rosenstock J, et al. (SURPASS-2 Investigators) (2021) · New England Journal of Medicine, 385(6):503-515.
    Primary head-to-head RCT: 1,879 adults with T2D; 40 weeks; evaluated tirzepatide 5, 10, 15 mg vs semaglutide 1.0 mg.
    Direct Source DOI: 10.1056/NEJMoa2107519 PubMed: 34170647
  2. Randomized controlled trial · Obesity
    Once-Weekly Semaglutide in Adults with Overweight or Obesity
    Wilding JPH, Batterham RL, Calanna S, et al. (STEP 1 Study Group) (2021) · New England Journal of Medicine, 384(11):989-1002.
    Key semaglutide weight-management RCT: 1,961 adults; 68 weeks; semaglutide 2.4 mg vs placebo.
    Direct Source DOI: 10.1056/NEJMoa2032183 PubMed: 33567185
  3. Randomized controlled trial · Obesity
    Tirzepatide Once Weekly for the Treatment of Obesity
    Jastreboff AM, Aronne LJ, Ahmad NN, et al. (SURMOUNT-1 Investigators) (2022) · New England Journal of Medicine, 387(3):205-216.
    Key tirzepatide weight-management RCT: 2,539 adults; 72 weeks; tirzepatide 5, 10, 15 mg vs placebo.
    Direct Source DOI: 10.1056/NEJMoa2206038 PubMed: 35658024
  4. Cardiovascular outcomes trial
    Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
    Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (SELECT Trial Investigators) (2023) · New England Journal of Medicine, 389(24):2221-2232.
    17,604 participants; 20% relative risk reduction in 3-point MACE; basis of FDA expanded indication for Wegovy.
    Direct Source DOI: 10.1056/NEJMoa2307563 PubMed: 37952131
  5. Renal outcomes trial
    Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
    Perkovic V, Tuttle KR, Rossing P, et al. (FLOW Trial Committees and Investigators) (2024) · New England Journal of Medicine, 391(2):109-121.
    3,533 participants; 24% risk reduction in major kidney disease events and CV death; stopped early for efficacy.
    Direct Source DOI: 10.1056/NEJMoa2403347 PubMed: 38785209
  6. Preclinical & molecular pharmacology
    LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
    Coskun T, Sloop KW, Loghin C, et al. (2018) · Molecular Metabolism, 18:3-14.
    Definitive characterization of tirzepatide structure, receptor affinities, and biased GLP-1 intracellular signaling.
    Direct Source DOI: 10.1016/j.molmet.2018.09.009 PubMed: 30473097
  7. Randomized withdrawal trial
    Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial
    Rubino D, Abrahamsson N, Davies M, et al. (STEP 4 Investigators) (2021) · JAMA, 325(14):1414-1425.
    Evaluated medication continuation versus placebo withdrawal, demonstrating weight regain after cessation.
    Direct Source DOI: 10.1001/jama.2021.3224 PubMed: 33755728
  8. Randomized withdrawal trial
    Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial
    Aronne LJ, Sattar N, Horn DB, et al. (SURMOUNT-4 Investigators) (2024) · JAMA, 331(1):38-48.
    Evaluated tirzepatide maintenance versus withdrawal, demonstrating substantial weight regain following cessation.
    Direct Source DOI: 10.1001/jama.2023.24945 PubMed: 38078870
  9. Primary randomized trial
    Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
    Aronne LJ et al. (2025).
    Read the comparator, population and prespecified endpoint; industry funded.
    Direct Source DOI: 10.1056/NEJMoa2416394 PubMed: 40353578
  10. Primary randomized trial
    Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes
    Nicholls SJ et al. (2025).
    Read the comparator, population and prespecified endpoint; industry funded.
    Direct Source DOI: 10.1056/NEJMoa2505928 PubMed: 41406444
  11. Official prescribing information
    Wegovy injection and tablets, current U.S. label
    DailyMed / National Library of Medicine (2026).
    Revised June 2026; checked 10 October 2026.
    Direct Source
  12. Official prescribing information
    Ozempic injection, current U.S. label
    DailyMed / National Library of Medicine (2026).
    Direct Source
  13. Official prescribing information
    Rybelsus and Ozempic tablets, current U.S. label
    DailyMed / National Library of Medicine (2026).
    Direct Source
  14. Official U.S. prescribing information
    Zepbound, current label
    DailyMed / National Library of Medicine (2026).
    Checked 10 October 2026.
    Direct Source
  15. Official U.S. prescribing information
    Mounjaro, current label
    DailyMed / National Library of Medicine (2026).
    Checked 10 October 2026; includes pediatric type 2 diabetes indication from age 10.
    Direct Source